A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects (SCANSMART)

July 15, 2014 updated by: Merck KGaA, Darmstadt, Germany

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study

The primary objective is to determine adherence to Rebif® New Formulation administered by RebiSmart during 12 weeks of therapy in patients with RRMS.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

61

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
    • Sandviksveien 178
      • Sandvika, Sandviksveien 178, Norway, N-1337
        • Sandvika Nevrosenter

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Neurology Clinics at Danish and Norwegian hospitals (single treatment group)

Description

Inclusion Criteria:

  • Males and females between 18 and 65 years of age
  • Have relapsing-remitting multiple sclerosis (RRMS) according to the revised McDonald Criteria (2005)
  • Having an expanded disability status scale (EDSS) of less than 6 at the screening visit or within 2 months prior to the screening visit
  • Stable treatment (defined as treatment after titration period) with RebiSmart administered Rebif new formulation (RNF) 22/44 mcg subcutaneously thrice a week for a minimum of 4 weeks prior to inclusion
  • Previously treated with disease modifying drugs (DMDs) for a minimum of 6 months prior to the screening visit

  • Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined by either:

    • Post-menopausal or surgically sterile; or
    • Using a highly effective method of contraception for the duration of the study. This is defined as a method that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly , and includes for instance implants, injectables, combined oral contraceptives, intra-uterine device (IUD), sexual abstinence or vasectomized partner
  • Have a scheduled visit 12 weeks after the inclusion visit
  • Willing and able to comply with the protocol for the duration of the study
  • Have given written informed consent

Exclusion Criteria:

  • Have had a relapse within 30 days prior to the first visit
  • Have any contra-indications to treatment with Interferon-beta 1a according to Summary of Product Characteristics
  • Have any other significant disease that in the Investigator's opinion would exclude the subject from the trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence assessment
Time Frame: 12 weeks
Adherence to RNF administered by RebiSmart during 12 weeks of therapy in patients with RRMS
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

Smerud Medical Research International AS
Merck Serono Norway

Investigators

  • Study Director: Medical Director, Merck Serono Norway

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (ACTUAL)

March 1, 2012

Study Registration Dates

First Submitted

May 17, 2010

First Submitted That Met QC Criteria

May 17, 2010

First Posted (ESTIMATE)

May 18, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

July 16, 2014

Last Update Submitted That Met QC Criteria

July 15, 2014

Last Verified

September 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EMR 701068-521

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Relapsing Remitting Multiple Sclerosis (RRMS)

Clinical Trials on RebiSmart

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe